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Editorial
O
n April 26, 2007, ABC 
World News, the American 
Broadcasting Corporation’s 
ﬂ  agship television news program, 
aired a “good news” story about a new 
test for prostate cancer [1]. Against 
a background of a dramatic graphic 
showing that 1.6 million American men 
undergo prostate biopsy each year, the 
presenter announced: “Researchers at 
Johns Hopkins say they have developed 
a more accurate blood screening 
test.” The story was based on a new 
study examining the performance 
of early prostate cancer antigen-2 as 
a serum marker for prostate cancer 
[2]. Unfortunately, ABC failed to 
disclose one crucial fact: the principal 
investigator of this study receives a 
share of the royalty sales of the test 
and is a paid consultant to the test’s 
manufacturer [3].
This failure was one of a litany of 
weaknesses in the story. There was 
no discussion, for example, of the 
scientiﬁ  c evidence showing that the 
test was “more accurate” than existing 
screening tests or of the uncertain 
beneﬁ  ts and proven harms of prostate 
cancer screening. In this month’s 
PLoS Medicine, Gary Schwitzer of the 
University of Minnesota School of 
Journalism and Mass Communication 
highlights this ABC broadcast as 
an example of particularly poor 
health reporting [4]. Schwitzer 
publishes an online project called 
HealthNewsReview.org (http://
HealthNewsReview.org/) that evaluates 
and grades media stories about 
new health interventions, notifying 
journalists of their grades. The project 
builds on other initiatives that monitor 
the quality of health reporting, such as 
the Australian Media Doctor Web site 
(http://www.mediadoctor.org.au/) 
and the United Kingdom’s Behind the 
Headlines project (http://www.nhs.
uk/News/Pages/NewsIndex.aspx). 
BBC News, The Guardian, and other 
news organizations covered a recent 
randomized controlled trial in PLoS 
Medicine on the effects of stopping 
or continuing antipsychotic drugs in 
Alzheimer disease [5], and Behind the 
Headlines posted a detailed assessment 
of the science behind the coverage [6].
HealthNewsReview.org uses a 
10-point grading scale. The rating 
criteria include whether a story 
adequately quantiﬁ  es the beneﬁ  ts of an 
intervention, appraises the supporting 
evidence, and gives information on 
the sources of a story and the sources’ 
competing interests. On this scale, the 
ABC story received a grade of just two. 
Based on the ratings of 500 stories from 
the highest circulation newspapers and 
news magazines, the most widely used 
wire service (Associated Press), and 
the three most popular US television 
networks, the report card from 
HealthNewsReview.org is grim. Most 
stories (62%–77%) failed to adequately 
address costs, harms, beneﬁ  ts, the 
quality of evidence, and the existence 
of other treatment options. The 
trouble with distorted journalistic 
reports, say David Ransohoff and 
Richard Ransohoff, is that they can 
generate false hopes and unwarranted 
fears [7]. Accurate, balanced, and 
complete health reporting is crucial, 
argues Schwitzer, so that “health care 
consumers are properly informed and 
ready to participate in decision making 
about their health care” [4].
The Origins of Unbalanced 
Reporting
When it comes to the quality of 
health reporting, why is the bar set so 
low? One problem is that today’s health 
reporters may have been covering 
crime last week and politics the week 
before. They have rarely been trained 
to understand the complexities of 
health research. For example, in 
her survey of 165 reporters in the 
US (response rate 69.6%), Melinda 
Voss found that 83% (96/115) had 
received no training in interpreting 
health statistics, and a third said that 
understanding key health issues was 
“often” or “nearly always” difﬁ  cult [8]. 
While there are certainly studies in 
specialist medical journals that will 
be difﬁ  cult for many people to grasp, 
nevertheless there may be some value 
in establishing a core set of scientiﬁ  c 
competencies for all health reporters. 
Indeed, the Association of Health Care 
Journalists’ Statement of Principles 
states that health reporters should 
“understand the process of medical 
research in order to report accurately” 
(http://www.healthjournalism.org/
secondarypage-details.php?id=56).
There is also a broader context 
in which medical stories get 
exaggerated—the 24-hour news cycle 
means that media organizations are 
battling for audience share, which in 
turn means that “the press has moved 
towards sensationalism, entertainment, 
and opinion” [9]. Headlines are often 
written by news editors, rather than the 
article’s reporter, and are particularly 
prone to exaggeration. All of this 
sensationalism strays far from the 
reality of biomedical research, a slow 
process that yields small, incremental 
results based on long-term studies that 
always have weaknesses. 
The origin of hype in health stories 
goes even deeper than journalists’ 
lack of training and the hurried 
pace of broadcasting. Ransohoff and 
Ransohoff have described medical 
researchers and reporters as “complicit 
collaborators,” both of whom may 
beneﬁ  t from a sensationalized story [7]. 
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Researchers beneﬁ  t from the publicity 
because it may increase citations to 
their study and help their chances of 
promotion or tenure, while a highly 
visible story of a dramatic medical 
breakthrough can boost a journalist’s 
career. Sensationalism occurs, they 
say, “when the participants stand 
to beneﬁ  t from publicity without a 
corresponding penalty for misleading 
reports.” HealthNewsReview.org could 
now provide such a penalty with its 
public naming and shaming of poor 
reporting, which in turn may drive 
journalists toward more balanced 
reporting. 
The Role of Medical Journals
When a health story gets hyped, 
it is all too easy for medical journal 
editors to deny any responsibility. 
The reality, of course, is that journal 
editors themselves are the third party 
in the “complicit collaboration”—the 
journal’s press release is the usual 
mechanism for linking the researcher 
to the journalist. Medical journals issue 
press releases about their upcoming 
studies partly because media publicity 
drives readers to the journal and 
builds brand recognition. A bland 
press release may be less likely to get 
your journal and the study noticed. 
Not surprisingly, a content analysis 
of journal press releases by Steven 
Woloshin and Lisa Schwartz found 
that these releases were themselves 
prone to exaggeration [10]; we suspect 
that press releases from research 
institutions and funding agencies 
may be equally as prone. Woloshin 
and Schwartz argue that all journal 
press releases should include: (1) a 
section putting results into context, 
(2) a section for the study’s limitations, 
(3) a statement of the study authors’ 
competing interests, and (4) a 
summary of the quantitative results 
expressed using absolute rather than 
just relative measures. 
Some commentators also feel that 
news embargoes—in which journals 
give reporters previews of an article if 
they promise not to report on it until 
an agreed-upon date—are merely a 
tool for a journal’s self-promotion 
[11]. While there may be some truth 
to that, Steve Connor, science editor 
of The Independent, has argued that 
abandoning embargoes could result in 
journalists trying to scoop each other, 
with the effect of lowering the quality 
of the coverage (http://www.plos.org/
cms/node/339). One advantage of an 
embargo is that we make the journal 
article available to the public at the 
same time as the news story appears.
Given PLoS’ core principle 
of “engag[ing] the interest and 
imagination of the public” (http://
www.plos.org/about/principles.html), 
we do invest resources into publicizing 
our papers. At PLoS Medicine, we try to 
predict which studies are likely to be 
of greatest public interest. An editor 
(not a press ofﬁ  cer) writes the press 
release, and we ask the study authors 
to fact-check it ahead of release. We 
strive to keep our press releases sober 
in tone to reduce the chances of 
media hype. We also write an Editors’ 
Summary published as part of the 
research article, which is aimed at non-
specialists and includes a discussion of 
the study’s implications and limitations. 
We ask all reporters to include a link 
in their story to the freely available 
PLoS Medicine study, so that readers can 
assess for themselves its strengths and 
weaknesses. And although we have no 
control over press releases issued by 
an author’s institution, we routinely 
ask to see these releases and will advise 
the institution’s press ofﬁ  cer if we feel 
that a release exaggerates the study’s 
ﬁ  ndings. 
Our “press release cycle” is, however, 
an imperfect art. We have no say over 
how authors present their work when 
they talk with reporters. We don’t 
always get our predictions right—we 
didn’t predict, for example, how 
much public interest there would 
be in a study examining acid-fast 
bacilli in tuberculosis-positive sputum 
[12], nor did we expect so little 
attention to a study on mental health 
disorders in Lebanon [13]. And we 
have occasionally seen our studies 
sensationalized. For example, a media 
storm (see http://www.plos.org/cms/
node/335) surrounded our publication 
of a meta-analysis of all pre-licensing 
trials submitted to the US Food and 
Drug Administration, including 
unpublished trials, on the efﬁ  cacy of 
certain antidepressants [14]. Although 
much of the reporting was balanced 
and insightful—highlighting the study’s 
ﬁ  nding that efﬁ  cacy was seen only in 
severe depression and questioning why 
trials go unpublished and why drugs get 
approved based on weak evidence—we 
also saw over-simpliﬁ  ed headlines such 
as “Antidepressant drugs don’t work.” 
The study’s public availability did at 
least allow clinicians, policy makers, 
and the public to discuss and debate 
the paper, and at the time of writing 
this editorial, we have posted 40 such 
Reader Responses [15]. 
A Shared Responsibility to Raise 
the Bar
Schwitzer’s alarming report card of 
the trouble with medical news stories is 
thus a wake-up call for all of us involved 
in disseminating health research—
researchers, academic institutions, 
journal editors, reporters, and media 
organizations—to work collaboratively 
to improve the standards of health 
reporting. The good news is that there 
are signs of change. Two years ago, 
Ray Moynihan and David Henry guest-
edited a special PLoS Medicine theme 
issue on disease mongering (http://
collections.plos.org/plosmedicine/
diseasemongering-2006.php), the 
corporate creation of new diseases in 
order to sell treatments. As they report 
in this month’s issue, over the last two 
years there has been a growing number 
of high-proﬁ  le articles on disease 
mongering, suggesting that “scepticism 
is building within the mainstream 
media” [16]. The Wall Street Journal, for 
example, recently ran a story on a new 
drug for restless legs syndrome under 
the headline “How Glaxo Marketed a 
Malady to Sell a Drug” [17]. 
There is other good news. Despite 
the risk that the media might over-
promote the ﬁ  ndings of genetic 
research (leading to so-called 
“genohype”), a study of 627 newspaper 
articles on gene discoveries found 
that only 11% contained such hype 
[18]. And if you want to see further 
proof that medical reporters can be 
healthily skeptical and nuanced in their 
reporting, take a look at the stories that 
were graded 10 out of 10 by Schwitzer’s 
project [4]. This is the kind of balanced 
journalism that we should all be 
working towards and one that helps to 
promote an informed and medically 
literate citizenry.  
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